Related Experiment Videos
Chemokines in inflammatory bowel disease
1Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, D-4063, Los Angeles, CA 90048, USA. Papadakisk@cshs.org
Current Allergy and Asthma Reports
|December 19, 2003
Summary
Inflammatory bowel diseases (IBD), like ulcerative colitis and Crohn's disease, involve gut inflammation. Chemokines, crucial for immune cell movement, are key to IBD development and may offer new therapeutic targets.
Area of Science:
- Gastroenterology
- Immunology
- Molecular Biology
Background:
- Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory conditions of the gastrointestinal tract.
- IBD pathogenesis involves leukocytic infiltration of the intestinal mucosa and submucosa, with transmural inflammation and granuloma formation characteristic of CD.
Purpose of the Study:
- To review recent advances in understanding the role of chemokines and their receptors in mucosal immunity and inflammation.
- To highlight the potential of chemokine/chemokine-receptor antagonists as novel therapeutic targets for human IBD.
Main Methods:
- Literature review of recent scientific advances.
- Analysis of the role of chemokines in leukocyte trafficking during inflammation.
- Discussion of therapeutic strategies targeting chemokine pathways.
Main Results:
- Chemokines are critical regulators of leukocyte trafficking in inflammatory conditions.
- Specific chemokines and their receptors are implicated in the pathogenesis of IBD.
- Targeting chemokine pathways presents a promising therapeutic avenue for IBD.
Conclusions:
- Chemokines play a significant role in the immune response within the gastrointestinal tract.
- Understanding chemokine involvement in IBD opens possibilities for targeted therapies.
- Chemokine antagonists represent a potential novel treatment strategy for inflammatory bowel diseases.